Pediatric Nephrology

, Volume 22, Issue 2, pp 222–231 | Cite as

Clinical outcomes of childhood lupus nephritis: a single center’s experience

  • Byong Sop Lee
  • Hee Yeon Cho
  • Eo Jin Kim
  • Hee Gyung Kang
  • Il Soo Ha
  • Hae Il Cheong
  • Joong Gon Kim
  • Hyun Soon Lee
  • Yong ChoiEmail author
Original Article


This study retrospectively reviewed the medical records of children with lupus nephritis (LN) who were treated at Seoul National University Children’s Hospital from 1986 to 2005 (mean duration 8.3±4.4 years). The records of 77 children (22 male and 55 female) were examined. The mean age at diagnosis was 11.9±3.0 years. The initial biopsy results revealed a WHO class IV classification for 60 (88.2%) of 68 biopsy proven cases. Of 77 patients, 67 (87.0%) responded initially to the high-dose corticosteroids with or without additional immunosuppressive therapy. Of the initial responders (67), 30 (44.8%) experienced at least one episode of proteinuric (24) or nephritic (6) flare. Thirteen patients (16.9%) progressed to either chronic renal failure (CRF) or end-stage renal disease (ESRD). Six (7.8%) patients died. A Kaplan–Meier estimate of patient survival and CRF-free survival rate was 95.4% and 88.7% at 5 years and 91.8% and 74.7% at 10 years, respectively. Multivariate analysis for class IV LN revealed male gender (P=0.029), initial hypertension (P=0.001) and absence of remission (P=0.002) to be prognostic factors predicting CRF. Glomerulosclerosis of 10% or more (P=0.005), nephritic flare (P=0.011), and presence of anti-phospholipid antibody (P=0.017) or syndrome (P=0.004) were also found to be independent risk factors for CRF. Cyclophosphamide pulse therapy failed to demonstrate superiority over other combined immunosuppressants used for the treatment of diffuse proliferative LN.


Lupus nephritis Risk factors Renal outcome Renal flare Anti-phospholipid antibody Cyclophosphamide pulse therapy 


  1. 1.
    Costallat LT, Coimbra AM (1994) Systemic lupus erythematosus: clinical and laboratory aspects related to age at disease onset. Clin Exp Rheumatol 12:603–607PubMedGoogle Scholar
  2. 2.
    Font J, Cervera R, Espinosa G, Pallares L, Ramos-Casals M, Jimenez S, Garcia-Carrasco M, Seisdedos L, Ingelmo M (1998) Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Ann Rheum Dis 57:456–459PubMedCrossRefGoogle Scholar
  3. 3.
    Gloor JM (1998) Lupus nephritis in children. Lupus 7:639–643PubMedCrossRefGoogle Scholar
  4. 4.
    Bakkaloglu A (2001) Lupus nephropathy in children. Nephrol Dial Transplant 16 [Suppl 6]:126–128PubMedGoogle Scholar
  5. 5.
    Perfumo F, Martini A (2005) Lupus nephritis in children. Lupus 14:83–88PubMedCrossRefGoogle Scholar
  6. 6.
    Klein-Gitelman M, Reiff A, Silverman ED (2002) Systemic lupus erythematosus in childhood. Rheum Dis Clin North Am 28:561–577PubMedCrossRefGoogle Scholar
  7. 7.
    Cameron JS (1999) Lupus nephritis. J Am Soc Nephrol 10:413–424PubMedGoogle Scholar
  8. 8.
    Emre S, Bilge I, Sirin A, Kilicaslan I, Nayir A, Oktem F, Uysal V (2001) Lupus nephritis in children: prognostic significance of clinicopathological findings. Nephron 87:118–126PubMedCrossRefGoogle Scholar
  9. 9.
    Barbano G, Gusmano R, Damasio B, Alpigiani MG, Buoncompagni A, Gattorno M, Perfumo F (2002) Childhood-onset lupus nephritis: a single-center experience of pulse intravenous cyclophosphamide therapy. J Nephrol 15:123–129PubMedGoogle Scholar
  10. 10.
    Bogdanovic R, Nikolic V, Pasic S, Dimitrijevic J, Lipkovska-Markovic J, Eric-Marinkovic J, Ognjanovic M, Minic A, Stajic N (2004) Lupus nephritis in childhood: a review of 53 patients followed at a single center. Pediatr Nephrol 19:36–44PubMedCrossRefGoogle Scholar
  11. 11.
    Wang LC, Yang YH, Lu MY, Chiang BL (2004) Retrospective analysis of the renal outcome of pediatric lupus nephritis. Clin Rheumatol 23:318–323PubMedCrossRefGoogle Scholar
  12. 12.
    Hagelberg S, Lee Y, Bargman J, Mah G, Schneider R, Laskin C, Eddy A, Gladman D, Urowitz M, Hebert D, Silverman E (2002) Long term follow up of childhood lupus nephritis. J Rheumatol 29:2635–2642PubMedGoogle Scholar
  13. 13.
    Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614–619PubMedCrossRefGoogle Scholar
  14. 14.
    Boumpas DT, Austin HA 3rd, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741–745PubMedCrossRefGoogle Scholar
  15. 15.
    Yee CS, Gordon C, Dostal C, Petera P, Dadoniene J, Griffiths B, Rozman B, Isenberg DA, Sturfelt G, Nived O, Turney JH, Venalis A, Adu D, Smolen JS, Emery P (2004) EULAR randomized controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 63:525–529PubMedCrossRefGoogle Scholar
  16. 16.
    Chan TM, Tse KC, Tang CS, Mok MY, Li FK; Hong Kong Nephrology Study Group (2005) Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16:1076–1084PubMedCrossRefGoogle Scholar
  17. 17.
    Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O’Nan P, Roth D (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971–980PubMedCrossRefGoogle Scholar
  18. 18.
    Baqi N, Moazami S, Singh A, Ahmad H, Balachandra S, Tejani A (1996) Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. J Am Soc Nephrol 7:924–929PubMedGoogle Scholar
  19. 19.
    Schwartz GJ, Brion LP, Spitzer A (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children and adolescents. Pediatr Clin North Am 34:571–590PubMedGoogle Scholar
  20. 20.
    Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C (1996) “Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 50:2047–2053PubMedGoogle Scholar
  21. 21.
    National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 [2 Suppl 1]:S1–S266Google Scholar
  22. 22.
    Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311PubMedCrossRefGoogle Scholar
  23. 23.
    Churg J, Bernstein J, Glassock RJ (1995) Renal disease. Ikagu-Shoin, Tokyo, pp 151–179Google Scholar
  24. 24.
    Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TT, Balow JE (1984) Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 25:689–695PubMedGoogle Scholar
  25. 25.
    Yoo CW, Kim MK, Lee HS (2000) Predictors of renal outcome in diffuse proliferative lupus nephropathy: data from repeat renal biopsy. Nephrol Dial Transplant 15:1604–1608PubMedCrossRefGoogle Scholar
  26. 26.
    Hong CY (2001) Pediatrics, 7th edn. Korean Textbook Press, Seoul, pp 1233–1237Google Scholar
  27. 27.
    Wang LC, Yang YH, Lu MY, Chiang BL (2003) Retrospective analysis of mortality and morbidity of pediatric systemic lupus erythematosus in the past two decades. J Microbiol Immunol Infect 36:203–208PubMedGoogle Scholar
  28. 28.
    Mok CC, Mak A, Chu WP, To CH, Wong SN (2005) Long-term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age-groups. Medicine (Baltimore) 84:218–224Google Scholar
  29. 29.
    Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Mejia JC, Aydintug AO, Chwalinska-Sadowska H, de Ramon E, Fernandez-Nebro A, Galeazzi M, Valen M, Mathieu A, Houssiau F, Caro N, Alba P, Ramos-Casals M, Ingelmo M, Hughes GR; European Working Party on Systemic Lupus Erythematosus (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82:299–308CrossRefGoogle Scholar
  30. 30.
    Lahita RG (1999) The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol 11:352–356PubMedCrossRefGoogle Scholar
  31. 31.
    Cameron JS (1994) Lupus nephritis in childhood and adolescence. Pediatr Nephrol 8:230–249PubMedCrossRefGoogle Scholar
  32. 32.
    Wallace DJ, Podell T, Weiner J, Klinenberg JR, Forouzesh S, Dubois EL (1981) Systemic lupus erythematosus—survival patterns. Experience with 609 patients. JAMA 245:934–938PubMedCrossRefGoogle Scholar
  33. 33.
    Ward MM, Studenski S (1990) Systemic lupus erythematosus in men: a multivariate analysis of gender differences in clinical manifestations. J Rheumatol 17:220–224PubMedGoogle Scholar
  34. 34.
    Austin HA 3rd, Boumpas DT, Vaughan EM, Balow JE (1994) Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 45:544–550PubMedGoogle Scholar
  35. 35.
    Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, Decker JL, Balow JE (1983) Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 75:382–391PubMedCrossRefGoogle Scholar
  36. 36.
    Nossent HC, Henzen-Logmans SC, Vroom TM, Berden JH, Swaak TJ (1990) Contribution of renal biopsy data in predicting outcome in lupus nephritis. Analysis of 116 patients. Arthritis Rheum 33:970–977PubMedGoogle Scholar
  37. 37.
    Schwartz MM, Lan SP, Bernstein J, Hill GS, Holley K, Lewis EJ (1992) Role of pathology indices in the management of severe lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group. Kidney Int 42:743–748PubMedGoogle Scholar
  38. 38.
    Magil AB, Puterman ML, Ballon HS, Chan V, Lirenman DS, Rae A, Sutton RA (1988) Prognostic factors in diffuse proliferative lupus glomerulonephritis. Kidney Int 34:511–517PubMedGoogle Scholar
  39. 39.
    Ioannidis JP, Boki KA, Katsorida ME, Drosos AA, Skopouli FN, Boletis JN, Moutsopoulos HM (2000) Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 57:258–264PubMedCrossRefGoogle Scholar
  40. 40.
    Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Pando J, Steinberg AD, Gourley MF, Klippel JH, Balow JE, Boumpas DT (2002) Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term follow up of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 46:995–1002PubMedCrossRefGoogle Scholar
  41. 41.
    El Hachmi M, Jadoul M, Lefebvre C, Depresseux G, Houssiau FA (2003) Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus 12:692–696PubMedCrossRefGoogle Scholar
  42. 42.
    Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C (1996) “Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 50:2047–2053PubMedGoogle Scholar
  43. 43.
    Massengill SF, Hedrick C, Ayoub EM, Sleasman JW, Kao KJ (1997) Antiphospholipid antibodies in pediatric lupus nephritis. Am J Kidney Dis 29:355–361PubMedGoogle Scholar
  44. 44.
    Bhandari S, Harnden P, Brownjohn AM, Turney JH (1998) Association of anticardiolipin antibodies with intraglomerular thrombi and renal dysfunction in lupus nephritis. QJM 91:401–409PubMedCrossRefGoogle Scholar
  45. 45.
    Frampton G, Hicks J, Cameron JS (1991) Significance of anti-phospholipid antibodies in patients with lupus nephritis. Kidney Int 39:1225–1231PubMedGoogle Scholar
  46. 46.
    Gulko PS, Reveille JD, Koopman WJ, Burgard SL, Bartolucci AA, Alarcon GS (1993) Anticardiolipin antibodies in systemic lupus erythematosus: clinical correlates, HLA associations, and impact on survival. J Rheumatol 20:1684–1693PubMedGoogle Scholar
  47. 47.
    Farrugia E, Torres VE, Gastineau D, Michet CJ, Holley KE (1992) Lupus anticoagulant in systemic lupus erythematosus: a clinical and renal pathological study. Am J Kidney Dis 20:463–471PubMedGoogle Scholar
  48. 48.
    Moroni G, Ventura D, Riva P, Panzeri P, Quaglini S, Banfi G, Simonini P, Bader R, Meroni PL, Ponticelli C (2004) Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 43:28–36PubMedCrossRefGoogle Scholar
  49. 49.
    Alarcon-Segovia D, Boffa MC, Branch W, Cervera R, Gharavi A, Khamashta M, Shoenfeld Y, Wilson W, Roubey R (2003) Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 12:499–503PubMedCrossRefGoogle Scholar
  50. 50.
    Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC (2004) Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 43:197–208PubMedCrossRefGoogle Scholar
  51. 51.
    Wetzels JF (2004) Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis? Neth J Med 62:347–352PubMedGoogle Scholar
  52. 52.
    Huong du L, Amoura Z, Duhaut P, Sbai A, Costedoat N, Wechsler B, Piette JC (2002) Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 29:2571–2576PubMedGoogle Scholar
  53. 53.
    Ioannidis JP, Katsifis GE, Tzioufas AG, Moutsopoulos HM (2002) Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J Rheumatol 29:2129–2135PubMedGoogle Scholar
  54. 54.
    Beimler JH, Andrassy K (2004) Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much? Pediatr Nephrol 19:949–955PubMedCrossRefGoogle Scholar
  55. 55.
    Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term follow up of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 50:3934–3940PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2006

Authors and Affiliations

  • Byong Sop Lee
    • 1
  • Hee Yeon Cho
    • 1
  • Eo Jin Kim
    • 1
  • Hee Gyung Kang
    • 1
  • Il Soo Ha
    • 1
  • Hae Il Cheong
    • 1
  • Joong Gon Kim
    • 1
  • Hyun Soon Lee
    • 2
  • Yong Choi
    • 1
    Email author
  1. 1.Department of PediatricsSeoul National University Children’s HospitalSeoulSouth Korea
  2. 2.Department of PathologySeoul National University College of MedicineSeoulSouth Korea

Personalised recommendations